secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-12-19T23:59:59+00:00
Accession:  0001558370-23-019911
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris cuts workforce 46%, expects ATI-1777 Phase 2b topline data in Jan 2024
------------------------------------------------------------------------------

- Workforce reduction of ~46%; one-time charge ~$3.1M in Q4 2023, total costs $5.0-5.3M over 12 months.
- ATI-1777 Phase 2a results published in JID Innovations; Phase 2b topline data expected January 2024.
- ATI-450 (zunsemetinib) repurposed for pancreatic cancer and metastatic breast cancer in collaboration with Washington University.
- ATI-2138 (ITK/JAK3) indication reassessed due to competitive landscape; guidance in early 2024.
- Company accelerating discovery programs from KINect platform to generate IND applications near term.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023019911/0001558370-23-019911-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023019911/acrs-20231219x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019911

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer